Companies Sight Sciences
Sight Sciences (SGHT): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Sight Sciences’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $3,902,022FY2023
- $3,022,179FY2024
- $2,005,608FY2025
CEO total pay was $2,005,608 in fiscal 2025, down from $3,022,179 in fiscal 2024.
FY2025: salary $659,000 · bonus $0 · stock awards $1,000,000 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Paul Badawi | $659,000 | $0 | $1,000,000 | $0 | $334,607 | $0 | $12,001 | $2,005,608 |
| President and Chief Executive Officer | ||||||||
| Alison Bauerlein | 474,900 | 0 | 950,000 | 0 | 196,504 | 0 | 5,250 | 1,626,754 |
| Chief Operating Officer | ||||||||
| Matthew Link | 288,125 | 0 | 480,000 | 0 | 0 | 0 | 448,793 | 1,216,918 |
| Chief Commercial Officer | ||||||||
| Jeremy Hayden | 433,000 | 0 | 390,000 | 0 | 146,571 | 0 | 4,683 | 974,254 |
| Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Paul Badawi | $2,005,608 | $3,022,179 | $3,902,022 | ↓ −1,016,571 |
| Alison Bauerlein | 1,626,754 | 2,238,543 | 1,848,183 | ↓ −611,789 |
| Matthew Link | 1,216,918 | — | 2,357,650 | — |
| Jeremy Hayden | 974,254 | 1,479,652 | — | ↓ −505,398 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to be competitive and appropriately balance our goals of attracting and retaining our executives and motivating them to achieve strategic objectives. In furtherance of our pay-for-performance philosophy, and to motivate and reward individual initiative and effort, a portion of each executive officer’s target annual compensation opportunity is variable based on our achievement relative to business and strategic objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jeremy Hayden | Option | 1,055 | 17.52 | — |
| Jeremy Hayden | RSU | 3,000 | — | 23,790 |
| Paul Badawi | Option | 7,319 | 17.52 | — |
| Jeremy Hayden | Option | 15,628 | 9.78 | — |
| Alison Bauerlein | Option | 19,722 | 10.1 | — |
| Alison Bauerlein | RSU | 21,569 | — | 171,042 |
| Paul Badawi | RSU | 21,950 | — | 174,064 |
| Jeremy Hayden | RSU | 22,935 | — | 178,822 |
| Alison Bauerlein | RSU | 51,500 | — | 408,395 |
| Paul Badawi | Option | 61,128 | 9.78 | — |
| Jeremy Hayden | RSU | 75,935 | — | 602,165 |
| Paul Badawi | RSU | 88,300 | — | 700,219 |
| Jeremy Hayden | RSU | 104,839 | — | 831,373 |
| Alison Bauerlein | RSU | 157,711 | — | 1,250,648 |
| Paul Badawi | RSU | 195,094 | — | 1,547,095 |
| Alison Bauerlein | RSU | 215,054 | — | 1,705,378 |
| Paul Badawi | RSU | 268,818 | — | 2,131,727 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gerhard BurbachIndependent · Compensation Committee (Chair) · Nominating and Corporate Governance Committee · Commercial Strategy Committee | $43,616 | $240,000 | — | — | — | $283,616 |
| Staffan EncrantzIndependent · Board Chair · Audit Committee · Nominating and Corporate Governance Committee (Chair) · Commercial Strategy Committee | 101,000 | 130,000 | — | — | — | 231,000 |
| Donald ZurbayIndependent · Audit Committee (Chair) · Compensation Committee | 72,500 | 130,000 | — | — | — | 202,500 |
| Catherine MazzaccoIndependent · Audit Committee · Commercial Strategy Committee (Chair) | 67,000 | 130,000 | — | — | — | 197,000 |
| Tamara Fountain, M.DIndependent | 59,606 | 130,000 | — | — | — | 189,606 |
| Erica RogersIndependent · Departed during FY | 55,733 | 130,000 | — | — | — | 185,733 |
| Brenda BeckerIndependent · Departed during FY | 48,556 | 130,000 | — | — | — | 178,556 |
| Paul BadawiEmployee director | — | — | — | — | — | 0 |
| David Badawi, M.DEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $130,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | We have adopted Stock Ownership Guidelines applicable to our executive officers and non-employee directors that ensure the interests of our executive officers and directors are aligned with those of our stockholders. |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $448,011 |
| Equity awards (grant-date value) | $1,020,000 |
| All other compensation | $0 |
| Total cost of the board | $1,468,011 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Sight Sciences as a peer
Companies that benchmark against SGHT
5 companies name SGHT as a compensation peer
- KESTRA MEDICAL TECHNOLOGIES, LTD.KMTSFY2026
- Outset Medical, Inc.OMFY2025
- Pulmonx CorpLUNGFY2025
- SERA PROGNOSTICS, INC.SERAFY2025
- SI-BONE, Inc.SIBNFY2025
- SkinHealth Systems Inc.SKINFY2025
Each company listed discloses SGHT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SGHT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies Sight Sciences names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | AxoGen | 2025 | Michael Dale | $775,865 | $7,342,895 | $0 | $906,133 | $9,047,454 |
| 2 | Si-BONE | 2025 | Laura Francis | 685,000 | 6,038,710 | 0 | 729,525 | 7,453,235 |
| 3 | Pulse Biosciences | 2025 | Paul LaViolette | 708,523 | 0 | 6,717,960 | 0 | 7,427,899 |
| 4 | CareDx | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 5 | Treace Medical Concepts | 2025 | John Treace | 755,353 | 4,635,000 | 0 | 0 | 5,405,190 |
| 6 | RxSight | 2025 | Ron Kurtz | 630,625 | 0 | 3,816,530 | 202,935 | 4,650,661 |
| 7 | CVRx | 2025 | Kevin Hykes | 660,533 | 1,270,080 | 1,516,896 | 444,492 | 3,905,801 |
| 8 | Senseonics Holdings | 2025 | Timothy Goodnow | 635,000 | 1,022,500 | 1,022,500 | 613,000 | 3,347,959 |
| 9 | OrthoPediatrics | 2025 | David Bailey | 550,000 | 2,445,200 | 0 | 322,281 | 3,331,481 |
| 10 | NeuroPace | 2025 | Joel Becker | 567,567 | 587,340 | 701,850 | 551,810 | 2,408,566 |
| 11 | Sight Sciences | 2025 | Paul Badawi | 659,000 | 1,000,000 | 0 | 334,607 | 2,005,608 |
| 12 | Zynex | 2024 | Thomas Sandgaard | 700,000 | 112,458 | 0 | 170,625 | 991,810 |
| 13 | iRadimed Corporation | 2025 | Roger Susi | 385,598 | 0 | 0 | 395,000 | 780,598 |
| — | ClearPoint Neuro | — | — | — | — | — | — | not in coverage universe |
| — | Tela Bio | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Sight Sciences | not disclosed | RSU 100 | not disclosed | Compensia, Inc. |
| AxoGen | 116.79% | PSU 50 · RSU 50 | No | Aon |
| CareDx | not disclosed | RSU 70 · PRSU 30 | No | Alpine Rewards |
| ClearPoint Neuro | not disclosed | not disclosed | not disclosed | not disclosed |
| CVRx | Kevin Hykes: 84%; Robert John: 66%; Philip Adamson: 84%% | Stock Options 50 · RSUs 50 | not disclosed | Aon |
| iRadimed Corporation | not disclosed | not disclosed | not disclosed | not disclosed |
| NeuroPace | not disclosed | not disclosed | not disclosed | Alpine, Inc. |
| OrthoPediatrics | 78.2% | RSU 100 | not disclosed | NFP Compensation Consulting |
| Pulse Biosciences | not disclosed | not disclosed | not disclosed | not disclosed |
| RxSight | 32.18% | Option 100 | not disclosed | Aon |
| Senseonics Holdings | not disclosed | not disclosed | not disclosed | Willis Towers Watson |
| Si-BONE | 106.5% | RSU 50 · PSU 50 | Yes — Relative TSR | Compensia, Inc. |
| Tela Bio | not disclosed | not disclosed | not disclosed | not disclosed |
| Treace Medical Concepts | not disclosed | RSU 50 · PSU 50 | No | Compensia, Inc. |
| Zynex | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (29 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Paul Badawi. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table” · page 41. As printed: 2,005,608. View filing ↗
- Section 01, Alison Bauerlein. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table” · page 41. As printed: 1,626,754. View filing ↗
- Section 01, Matthew Link. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table” · page 41. As printed: 1,216,918. View filing ↗
- Section 01, Jeremy Hayden. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table” · page 41. As printed: 974,254. View filing ↗
- Section 08, Gerhard Burbach. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 283,616. View filing ↗
- Section 08, Staffan Encrantz. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 231,000. View filing ↗
- Section 08, Donald Zurbay. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 202,500. View filing ↗
- Section 08, Catherine Mazzacco. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 197,000. View filing ↗
- Section 08, Tamara Fountain, M.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 189,606. View filing ↗
- Section 08, Erica Rogers. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 185,733. View filing ↗
- Section 08, Brenda Becker. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 178,556. View filing ↗
- Section 08, Paul Badawi. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, David Badawi, M.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 448,011 + equity 1,020,000 + all other 0 = 1,468,011, summed across the director compensation table rows.
- AxoGen, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in AxoGen's own proxy. As printed: 9,047,454. View filing ↗
- Si-BONE, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Si-BONE's own proxy. As printed: 7,453,235. View filing ↗
- Pulse Biosciences, Section 10b CEO total. DEF 14A, filed 2026-05-11. CEO total compensation as printed in Pulse Biosciences's own proxy. As printed: 7,427,899. View filing ↗
- CareDx, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in CareDx's own proxy. As printed: 7,179,699. View filing ↗
- Treace Medical Concepts, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Treace Medical Concepts's own proxy. As printed: 5,405,190. View filing ↗
- RxSight, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in RxSight's own proxy. As printed: 4,650,661. View filing ↗
- CVRx, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in CVRx's own proxy. As printed: 3,905,801. View filing ↗
- Senseonics Holdings, Section 10b CEO total. DEFR 14A, filed 2026-04-09. CEO total compensation as printed in Senseonics Holdings's own proxy. As printed: 3,347,959. View filing ↗
- OrthoPediatrics, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in OrthoPediatrics's own proxy. As printed: 3,331,481. View filing ↗
- NeuroPace, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in NeuroPace's own proxy. As printed: 2,408,566. View filing ↗
- Sight Sciences (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Sight Sciences's own proxy. As printed: 2,005,608. View filing ↗
- Zynex, Section 10b CEO total. DEF 14A, filed 2025-03-28. CEO total compensation as printed in Zynex's own proxy. As printed: 991,810. View filing ↗
- iRadimed Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in iRadimed Corporation's own proxy. As printed: 780,598. View filing ↗
- Section 10a, Si-BONE reciprocity. DEF 14A. Si-BONE names Sight Sciences in its own disclosed peer group (read from its most recent proxy). View filing ↗